

| Activities | Screening | Baseline | Day of Surgery | Early PostOP | FU d3 | FU d14 | FU d30 | FU every 12w |
|---|-----------|----------|----------------|--------------|-------|--------|--------|--------------|
| I/E criteria | ✓ | - | - | - | - | - | - | - |
| Demographics, medical history | ✓ | - | - | - | - | - | - | - |
| Written informed consent | - | ✓ | - | - | - | - | - | - |
| Vital signs (heart frequency, blood pressure, body temperature), weight | - | ✓ | - | ✓ | ✓ | ✓ | ✓ | ✓ |
| Physical examination | - | ✓ | - | ✓ | ✓ | ✓ | ✓ | ✓ |
| Neurological examination (NANO scale) | - | ✓ | - | ✓ | ✓ | ✓ | ✓ | ✓ |
| Orthoptic examination | - | ✓ | - | - | - | ✓ | - | - |
| Seizure status (ILAE) | - | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ |
| Current medication (including steroids) | - | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ |
| ASA score | - | ✓ | - | - | - | - | - | - |
| KPS | - | ✓ | - | ✓ | ✓ | ✓ | ✓ | ✓ |
| MMSE | - | ✓ | - | - | - | ✓ | ✓ | ✓ |
| Modified Rankin score (mRS) | - | ✓ | - | ✓ | ✓ | ✓ | ✓ | ✓ |
| Neurocognitive testing (VLMT, Boston Naming test, EpiTrack®) | - | ✓ | - | - | - | - | ✓ | ✓ |
| QoL questionnaire (EORTC-QLQ-C30 and BN20) | - | ✓ | - | - | - | ✓ | ✓ | ✓ *** |
| Complete blood count | - | ✓ | - | ✓ | ✓ | - | - | - |
| Coagulation analysis (including preoperative tests as specified in 2.7) | - | ✓ | - | ✓ | - | - | - | - |
| Serum chemistry | - | ✓ | - | ✓ | ✓ | - | - | - |
| Pregnancy test ** | - | ✓ | - | - | - | - | - | - |
| Gadolinium-enhanced MRI | - | ✓ | - | - | ✓ | - | - | ✓ |
| EEG | - | ✓ | - | - | - | - | ✓ | - |
| Adverse events (CTCAE) | - | - | ✓ | ✓ | ✓ | ✓ | ✓ | - |
| Randomization | - | - | ✓ | - | - | - | - | - |

| | | | | | | | | |
|--|---|---|---|---|---|---|---|-------|
| Surgery-related data (IOM, duration, blood loss, intraoperative seizures etc.) | - | - | ✓ | - | - | - | - | - |
| Survival status * | - | - | - | ✓ | ✓ | ✓ | ✓ | ✓ |
| Periprocedural adverse events (PSIs, CSCs) | - | - | - | ✓ | ✓ | ✓ | ✓ | ✓**** |
| Length of mechanical ventilation | - | - | - | ✓ | ✓ | ✓ | - | - |
| Histopathological results | - | - | - | - | - | - | ✓ | - |
| Length of hospital stay | - | - | - | - | - | ✓ | ✓ | ✓ |
| Radiotherapy (day of start, number of days, total Gy) | - | - | - | - | - | ✓ | ✓ | ✓ |
| Tumor-directed medical therapy (drug, dose, schedule) | - | - | - | - | - | ✓ | ✓ | ✓ |
| Other tumor-directed treatment (e.g. TTFs) | - | - | - | - | - | ✓ | ✓ | ✓ |
| Assessment of progression (RANO 2.0 criteria) | - | - | - | - | - | - | - | ✓ |